Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 10/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 5/20 | 0.39 |
| ▸ | RAB9A | P51151 | 5/20 | 0.39 |
| ▸ | PKM | P14618 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.36 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | WDR91 | A4D1P6 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9910035 | 0.82 | HDAC1 (0.46) | HDAC1HDAC6HDAC2HDAC8NPC1 | |
| SCHEMBL1920137 | 0.76 | NPC1 (0.47) | HDAC1HDAC6HDAC2HDAC8NPC1 | |
| SCHEMBL1919491 | 0.73 | ALDH1A1 (0.43) | HDAC1HDAC6HDAC2HDAC8NPC1 | |
| SCHEMBL197516 | 0.69 | GAA (0.39) | HDAC1HDAC6HDAC2HDAC8NPC1 | |
| SCHEMBL197987 | 0.69 | HDAC2 (0.48) | HDAC1HDAC2HDAC3 | |
| SCHEMBL3348291 | 0.68 | AKT1 (0.38) | HDAC1MAPTALDH1A1 | |
| SCHEMBL3350719 | 0.67 | AKT1 (0.39) | MAPTALDH1A1L3MBTL1 | |
| SCHEMBL3352336 | 0.66 | HDAC1 (0.45) | HDAC1HDAC6NPC1RAB9AMAPT | |
| SCHEMBL1918853 | 0.65 | HDAC1 (0.34) | HDAC1HDAC6HDAC2HDAC8HDAC3 | |
| SCHEMBL199575 | 0.63 | HDAC1 (0.46) | HDAC1HDAC6HDAC2HDAC8NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198299-B2 | Cycloalkylidene and heterocycloalkylidene inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-20120045412-A1 | CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120045412-A1 | CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS | HDAC1, HDAC11, HDAC2 | HDAC1 1/4885HDAC6 7/4885HDAC2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.